Core Insights - Certara's software bookings have shown a deceleration, with a 6% year-over-year decline in Q4, impacting the company's revenue growth outlook for 2026, which is projected to be flat to 4% [2][6][4] - The company reported that organic software revenue growth for 2025 was 7%, aligning with internal expectations, while EBITDA margin reached 32%, at the high end of guidance [3][4] - Certara's growth initiatives focus on biosimulation, particularly in quantitative systems pharmacology (QSP), Simcyp, and PBPK services, alongside AI and cloud offerings [5][11][12] Software Bookings and Revenue Outlook - The decline in software bookings is attributed to customer reprioritization and lagging study counts from slower clinical trial starts, which are expected to pressure future bookings [6][4] - Certara's organic trailing-twelve-month software bookings growth rate was approximately 1% for the previous year, indicating a need for improvement in this area [2][6] Services Performance - Certara's services segment has shown low-single-digit growth, averaging around 3% over the last three years, with a strong performance in December suggesting market stability [8][6] - The company noted that services bookings can be volatile, with significant fluctuations observed between quarters [8] Customer Segments and Market Dynamics - Tier-three customers, including biotechs, performed well, benefiting from an easing funding environment, while tier-one customers are expected to show stability despite past volatility [9] - The company anticipates that the reprioritization and headcount reductions affecting tier-one customers are largely behind them, although they may still impact near-term revenue [9] Growth Areas and AI Integration - Demand for model-informed drug development (MIDD) and biosimulation remains strong, with QSP and AI-enabled offerings being key growth areas [11][12] - Certara's acquisition of Vyasa in 2022 has allowed the integration of AI technology into its products, enhancing capabilities and customer value [12][13] Operational Priorities and Capital Allocation - Under new leadership, Certara aims to align its software and services offerings more closely, adopting a customer-centric approach [14] - The company plans to maintain an EBITDA margin of 30% to 32% while investing in R&D, particularly in MIDD and biosimulation, and has identified $10 million in cost avoidance for 2026 [15][16] Industry Trends and Opportunities - The industry is gradually shifting towards alternatives to animal model studies, presenting a significant opportunity for Certara in biosimulation, although adoption may take time due to risk aversion in pharma [17]

Summary of Certara Conference Call Company Overview - **Company**: Certara - **Industry**: Healthcare technology and distribution, specifically focusing on biosimulation and Model-Informed Drug Development (MIDD) Key Points and Arguments Financial Performance - **Q4 Performance**: Revenue and EBITDA were in line with expectations, with organic software revenue growth for 2025 at 7% [3][4] - **EBITDA Margin**: Achieved a high end of the original guidance at 32% [3][4] - **2026 Revenue Guidance**: Projected growth is flat to 4%, influenced by a deceleration in software bookings [4][7] - **Bookings Decline**: Q4 software bookings decreased by 6% year-over-year, attributed to customer dynamics and reduced seat licenses in the Phoenix product [4][5] Market Dynamics - **Customer Behavior**: Noted a shift in customer dynamics, particularly among large pharma clients, impacting software bookings [4][5] - **Services Revenue**: Services revenue has grown at a low single-digit rate (approximately 3%) over the last three years, with a strong December performance [6][7] - **End Market Outlook**: Anticipated stable market conditions with potential tailwinds, particularly in services [9][43] Leadership and Strategy - **New CEO**: Jon Resnick has been appointed, bringing a fresh perspective and a focus on customer-centricity [10][15] - **Operational Changes**: Emphasis on aligning software and services offerings to better meet customer needs [15][16] - **Incentive Structure**: Plans to unify incentives across the organization to enhance collaboration between software and services [17] Product Development and AI Integration - **AI Strategy**: Certara has integrated AI technology from the acquisition of Vyasa, launching Certara IQ for Quantitative Systems Pharmacology (QSP) [22][23] - **Growth Areas**: QSP, Simcyp, and PBPK services are identified as fast-growing segments within the organization [12][30] - **Human in the Loop**: Certara's model requires scientific expertise alongside software, creating a competitive advantage [34] Regulatory and Market Evolution - **Biosimulation Role**: Certara is positioned to lead in biosimulation as the industry shifts away from animal model studies, which are seen as less effective [35][36] - **Market Adaptation**: The company is adapting to changes in disease focus areas among biopharma clients, maintaining flexibility to meet evolving demands [40][41] M&A and Capital Allocation - **M&A Appetite**: Certara is open to pursuing tuck-in acquisitions, supported by a strong balance sheet and cash position [44][45] - **Share Repurchase Program**: The company has initiated a share repurchase program as part of its capital allocation strategy [46] Overall Sentiment - **Optimism for 2026**: Certara expresses excitement about internal changes and operational initiatives that could lead to improved performance [47][48] - **Conservatism in Guidance**: The company has set conservative guidance to build a solid foundation for future growth, reflecting a cautious but optimistic outlook [47][48]

Summary of Certara's Conference Call Company Overview - **Company**: Certara - **Industry**: Healthcare technology and distribution, specifically focusing on biosimulation and drug development Key Financial Highlights - **Q4 Performance**: Revenue and EBITDA were in line with expectations, with organic software revenue growth of 7% for 2025, and EBITDA margin at 32%, which was at the high end of guidance [3][4] - **2026 Revenue Guidance**: Projected revenue growth is flat to 4%, influenced by a 1% organic TTM software bookings and a -6% year-on-year decline in Q4 software bookings [4][5] - **Services Revenue**: Low single-digit growth of about 3% over the last three years, with a strong December in services bookings indicating potential stability in the market [6][7] Market Dynamics - **Customer Dynamics**: Notable deceleration in software bookings attributed to macro customer reprioritization and a decrease in study counts on Pinnacle 21 [4][5] - **End Market Outlook**: Despite challenges, there is an expectation of a stable market with potential tailwinds, particularly in services [7][8] Product and Service Insights - **Software and Services**: Strong demand for Model-Informed Drug Development (MIDD) and biosimulation services, particularly in QSP, Simcyp, and PBPK services [12][13] - **AI Integration**: Certara is integrating AI capabilities into its products, with the launch of Certara IQ for QSP and enhanced functionalities in Phoenix Cloud [26][27] Leadership and Strategic Changes - **New CEO**: Jon Resnick's appointment is expected to bring a customer-centric approach and improve commercial execution [9][15] - **Operational Changes**: Focus on aligning incentives across software and services to enhance customer engagement and operational efficiency [16][17] Research and Development - **Investment in R&D**: Continued investment in R&D is planned, particularly in MIDD and biosimulation, while maintaining EBITDA margins between 30%-32% [19][20] - **Cost Management**: Identified $10 million in cost avoidance to support investments while maintaining financial discipline [21] Future Opportunities - **Biosimulation's Role**: Certara is positioned to lead in the shift towards biosimulation as a replacement for traditional animal model studies, aiming to help biopharma companies reduce R&D costs and time [38][39] - **M&A Potential**: Certara has a strong balance sheet and is open to tuck-in acquisitions while also considering share repurchase as a capital allocation strategy [48][49] Conclusion - Certara is navigating a challenging market environment with a focus on operational improvements, strategic investments in AI and R&D, and leveraging its leadership position in biosimulation to drive future growth. The company is optimistic about stabilizing market conditions and the potential for increased demand in its services and software offerings [50][51]

Summary of Certara FY Conference Call (March 03, 2026) Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Biotechnology and Pharmaceutical Services Key Points and Arguments Leadership Transition - John Gallagher, the new CFO, has been in the role for approximately 61-62 days and is focused on transitioning from fact-finding to actionable solutions for business growth [7][8][9] - The management team expresses optimism about the company's potential and the quality of its products and personnel [8][9] Growth Drivers - Certara has several market-leading products with growth potential, particularly in the MIDD (Model-Informed Drug Development) and Biosimulation sectors, which constitute about two-thirds of the business [12][13] - The company aims to enhance operational execution and customer-centricity, focusing on strategic clarity and disciplined product management [14][15] Regulatory Services Business - There is ongoing discussion about the future of the Regulatory services business, with mixed opinions on whether to sell or retain it. The business has shown resilience despite market pressures [17][19][22] - The CFO noted a 1.5 book-to-bill ratio in December, indicating strong performance despite external pressures [18][19] Financial Outlook - For FY 2026, Certara expects flat to 4% growth in top-line revenues, with low single-digit growth anticipated for both software and services [32][34][36] - The company reported a strong EBITDA margin of 32% for the previous year and aims to maintain similar margins despite increased investments in growth areas [46][48] AI Integration and Innovation - Certara is embedding AI capabilities into its existing products, such as Phoenix Cloud and Certara IQ, which are expected to drive growth in the near term [50][52] - The company anticipates that AI will enhance both technology and service offerings, with a focus on customer adoption and integration [54][55] Regulatory Relationships - Certara has established strong relationships with over 20 regulators globally, which aids in facilitating communication between biopharma customers and regulatory bodies [30][31] - The company is optimistic about the positive regulatory environment and its potential to drive business growth [30] Future Catalysts - Key growth catalysts include the transition of tier 1 customers to the cloud version of Phoenix and developments in QSP (Quantitative Systems Pharmacology) [61][62] - Certara is exploring new metrics to better communicate its growth and value beyond traditional service versus software bookings [63][64] Additional Important Insights - The management emphasizes the importance of innovation and operational changes to leverage external partnerships effectively [58] - The company is focused on understanding customer needs and enhancing its offerings to meet those demands [56][57] This summary encapsulates the critical insights from the Certara FY Conference Call, highlighting the company's strategic direction, financial outlook, and growth opportunities within the biotechnology and pharmaceutical services industry.

Summary of Simulations Plus FY Conference Call Company Overview - **Company**: Simulations Plus (NasdaqGS:SLP) - **Industry**: Biosimulation and Drug Development Key Points Differentiating Features of Simulations Plus Platform - Simulations Plus offers several biosimulation solutions, including ADMET Predictor, GastroPlus, Monolix, and Pro-ficiency, characterized by their ease of use and scientific functionality [4][5][6] - The company emphasizes the accuracy of its predictive outputs, particularly in the discovery space, where ADMET Predictor consistently outperforms competitors [5] - Monolix is noted as the highest growth software platform due to its workflow orientation and integration capabilities [6] Customer Segmentation and Revenue Mix - The customer base is approximately 75% large pharma and 25% biotech, with revenues driven 80% from clinical applications and 20% from discovery [8][9] - The company anticipates a consistent revenue mix of 60-65% from software and 35-40% from services, with a long-term goal to increase software revenue to 70% [16][17] Financial Guidance and Growth Expectations - For FY 2026, the company has set a conservative growth guidance of 0%-4%, reflecting a cautious outlook based on previous year comparisons [10][14] - The first quarter showed overperformance in service business, with a backlog at two-year highs, indicating potential for growth in the latter half of the fiscal year [11][12] Strategic Initiatives and Product Development - The company is focusing on maximizing existing products while also developing a new product roadmap that integrates AI capabilities into their biosimulation ecosystem [22][23] - The integration of AI is expected to enhance productivity and efficiency, potentially allowing for new pricing models and revenue streams [30][31] Regulatory Environment and Market Trends - The FDA's push for alternative methodologies is seen as a long-term opportunity, with expectations for meaningful adoption and revenue impact within 2-3 years [35][40] - Simulations Plus is well-positioned to leverage its tools, such as GastroPlus and QSP capabilities, to meet evolving regulatory requirements and reduce reliance on animal testing [38][39] Competitive Landscape and Market Position - The company views AI as a tool that enhances its existing capabilities rather than a direct competitor, with many AI startups becoming clients rather than replacing Simulations Plus' offerings [48][49] - The historical context of AI adoption in drug development suggests that the company will continue to play a significant role in the biosimulation market [49] Additional Insights - The company is reorganizing its sales strategy to focus on cross-selling its full suite of platforms, which is expected to drive growth [20][21] - There is a recognition of the importance of data management and integration as pharma companies invest in AI, which aligns with Simulations Plus' product development strategy [43][44] This summary encapsulates the key insights from the conference call, highlighting the company's strategic direction, market positioning, and growth expectations in the biosimulation industry.

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.6 million, representing a year-over-year growth of 3% on a reported basis and 2% on a constant currency basis [19] - For the full year 2025, total revenue was $418.8 million, reflecting a year-over-year growth of 9% on a reported basis and 8% on a constant currency basis [19] - Adjusted EBITDA for Q4 2025 was $32.5 million, a decrease from $33.5 million in Q4 2024, with an adjusted EBITDA margin of 31% [24] - Net loss for Q4 2025 was $5.9 million, compared to net income of $6.6 million in Q4 2024 [25] - Adjusted diluted earnings per share for Q4 2025 was $0.09, down from $0.15 in the same quarter last year [26] Business Line Data and Key Metrics Changes - Software revenue in Q4 2025 was $46.4 million, up 10% year-over-year, driven by MIDD software and Pinnacle 21 [20] - Services revenue for Q4 2025 was $57.3 million, down 1% year-over-year [22] - Software bookings in Q4 2025 were $56.1 million, down 6% from the prior year period [21] - MIDD services bookings saw double-digit growth in Q4, with growth led by Tiers 2 and 3 [23] Market Data and Key Metrics Changes - The pharmaceutical industry is spending over $200 billion annually on drug development, with timelines extending to 10-15 years [6] - Certara has over 2,600 customers and 23 regulatory agencies using its technologies [9] Company Strategy and Development Direction - The company aims to sharpen operations, focus investments, and execute with greater discipline to capture market opportunities [5] - Certara plans to enhance AI integration and focus on core R&D technologies and model-informed drug development (MIDD) [16] - The company is undergoing a strategic review of its regulatory writing and operations business to maximize long-term shareholder value [13] Management's Comments on Operating Environment and Future Outlook - Management expressed that 2026 will be a transition year with guidance for flat to low single-digit revenue growth, reflecting market conditions and planned operational improvements [17] - The company believes it can achieve double-digit growth over time, although it did not provide a specific timeline [90] Other Important Information - Certara repurchased approximately 3.3 million shares for $43 million during 2025 [26] - The company has identified approximately $10 million in cost avoidance for 2026 compared to prior planning [24] Q&A Session Questions and Answers Question: What attracted you to Certara and how do you view the differentiation of its software products? - The new CEO highlighted the compelling market opportunity and the strong track record of Certara's software products being deeply embedded in customer workflows [32][34] Question: How does the platform approach and cross-selling factor into the customer-centric strategy? - The CEO emphasized that the strategy remains focused on serving existing users while enhancing engagement at senior levels to drive innovation [38] Question: Can you break down the revenue guidance for 2026? - Management indicated that the guidance reflects low single-digit growth due to stable end markets and a deceleration in software bookings [43] Question: What are the opportunities for AI enablement? - AI is being actively embedded into core assets, with a focus on enhancing product functionality and improving operational efficiency [54][58] Question: What are the lowest hanging fruit in revamping the commercial organization? - The CEO mentioned optimizing customer relationships, pricing, and operational elements as immediate areas of focus [62]

Financial Data and Key Metrics Changes - Revenue for fiscal year 2025 increased by 13% to $79.2 million, while total revenue for the fourth quarter decreased by 6% to $17.5 million [4][10] - Adjusted EBITDA grew by 8%, and adjusted EPS also increased by 8% for the fiscal year [4] - Total gross margin for the fiscal year was 58%, down from 62% in the prior year, with software gross margin decreasing from 84% to 79% [13][15] Business Line Data and Key Metrics Changes - Software revenue decreased by 9% in Q4, representing 52% of total revenue, while services revenue decreased by 3%, representing 48% [10] - For the fiscal year, software revenue increased by 12%, accounting for 58% of total revenue, and services revenue increased by 15%, accounting for 42% [10] - Specific product performance: Admet Predictor declined by 10% in Q4 but grew by 5% for the fiscal year; GastroPlus declined by 3% in Q4 but grew by 1% for the fiscal year; Monolith Suite grew by 3% in Q4 and 14% for the fiscal year [11] Market Data and Key Metrics Changes - The company noted early signs of stabilization in the market, with large pharma gaining clearer visibility into pricing frameworks and biotech funding improving modestly [5][6] - Proposal activity and conference engagement have strengthened, indicating a more confident budgeting cycle among clients [5] Company Strategy and Development Direction - The company completed a strategic reset in fiscal 2025, transitioning to a unified operating model that aligns product and technology with client-focused services [4] - The focus for fiscal 2026 includes enhancing biosimulation capabilities, integrating AI into workflows, and developing a connected ecosystem of products [8][9] - The company aims to support clients through discovery, clinical development, and commercialization with a modern, interoperable biosimulation ecosystem [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the future, noting that while uncertainty persists, there are positive trends in biotech funding and client budgeting [5][6] - The company anticipates a stable operating environment for fiscal 2026, with guidance for total revenue between $79 million and $82 million, reflecting year-over-year growth of 0%-4% [16] Other Important Information - The company ended the fiscal year with $32.4 million in cash and short-term investments, remaining well-capitalized with no debt [15][16] - The effective tax rate for the fiscal year was 7%, with expectations for fiscal 2026 to be in the range of 12%-14% [15] Q&A Session Summary Question: Update on demand environment and trends - Management noted an uptick in biotech funding and positive discussions with clients regarding proposals and budgeting for the next year [21][22] Question: Feedback on GastroPlus release with AI capabilities - Initial responses to the AI-infused GastroPlus have been positive, with clients eager to leverage AI capabilities [24][25] Question: Factors affecting large pharma spending - Management indicated that while there are positive trends, caution remains due to individual client circumstances and the overall budgeting cycle [31][32] Question: Guidance assumptions and potential biotech recovery - The guidance assumes continued cautious optimism in biotech funding but does not project a significant uptick in revenue from this sector for 2026 [43][44] Question: Renewal rates and factors affecting them - Renewal rates have been impacted by client consolidations and budget scrutiny, but management expects improvement as clients have already reviewed their module needs [52][54] Question: Proficiency asset performance - Proficiency software revenue declined by 63% in Q4, while Med-Com services grew by 70%, indicating mixed performance post-acquisition [62][63] Question: Cash flow outlook and acquisition interest - Cash flow remains robust, and the company is actively looking for acquisition opportunities in biosimulation and clinical operations [72][73] Question: Pricing flexibility and plans for 2026 - The company plans to implement more aggressive pricing due to new AI capabilities, with expectations for a positive impact on renewal rates [76][77]

Summary of Certara Conference Call Company Overview - **Company**: Certara - **Industry**: Pharmaceutical services supply chain, focusing on biosimulation and regulatory services Key Points Q3 Results and Market Reaction - Certara experienced a slowdown in bookings at the end of Q3, which alarmed the market [4] - The company had lower-than-expected bookings, particularly in the regulatory business, which has been volatile [5] - Despite the slowdown, Certara reported strong results with tier three biotech clients, indicating a successful strategy focusing on venture capital companies [4][6] Regulatory Business Review - The regulatory business has been under strategic review for over a year due to volatility and current disruptions at the FDA [8] - Certara expects the regulatory environment to stabilize by 2026, but the business is not considered strategically important as it once was [9][11] Biosimulation and Market Trends - Certara holds a leadership position in biosimulation, benefiting from FDA initiatives to reduce animal testing [12][15] - The company is seeing increased interest in biosimulation from clients, particularly in monoclonal antibody development [13][14] - Certara's QSP (Quantitative Systems Pharmacology) business is growing, with the launch of Certara IQ aimed at becoming a standard software product in the market [35] Service Bookings and Client Dynamics - Tier three services have been strong, while tier one clients showed a slowdown in service bookings [20] - Certara has focused on financial sponsors and larger VCs to stabilize its client base [21] - The company has a large backlog of work, indicating potential for future growth as the market recovers [22] Pricing Environment - The current pricing environment is weaker, with mid-single-digit pricing increases on software products being tempered [24] - Certara is prioritizing the growth of biosimulation usage over immediate price increases [24] Product Development and Innovation - Certara has expanded its software offerings, including new versions of Simcyp targeted at preclinical and formulation scientists [28][29] - The company is evolving its software portfolio into a cloud-based platform, with plans for further integration and AI enhancements by 2026 [39][41] Economic and Regulatory Pressures - Certara faces hesitancy from clients to spend due to uncertainties in the regulatory environment and macroeconomic factors [44] - Despite these challenges, there is a long-term trend towards increased interest in modeling as a cost-effective solution in pharma [45][46] Conclusion - Certara is navigating a complex environment with both challenges and opportunities, particularly in biosimulation and regulatory services, while maintaining a strong pipeline and backlog of work [22][23]

Third Quarter 2025 Financial Results November 6, 2025 Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the "Company," "Certara," "we," "us," and "our" refer to Certara, Inc. and its consolidated subsidiaries. Trademarks and Service Marks The Certara design logo, "Certara," and ou ...

Core Insights - Certara, Inc. reported a total revenue of $104.6 million for Q3 2025, reflecting a year-over-year growth of 10% [4][8] - The company has raised its profitability targets for 2025 and narrowed its revenue guidance to a range of $415 million to $420 million [3][15] - The CEO emphasized the launch of new software products, particularly CertaraIQ for QSP modeling, aimed at enhancing biosimulation technology in drug development [3] Financial Performance - Total revenue for Q3 2025 was $104.6 million, with software revenue at $43.8 million (22% growth) and services revenue at $60.8 million (3% growth) [4][5][8] - Total bookings reached $96.6 million, a 1% increase year-over-year, with software bookings growing by 17% [6][8] - Net income for Q3 2025 was $1.5 million, a significant improvement from a net loss of $1.4 million in Q3 2024, marking a 211% increase [12][8] Cost and Expenses - Total operating expenses for Q3 2025 were $61.9 million, up from $55.0 million in Q3 2024, primarily due to increased employee-related costs and stock-based compensation [10][8] - The cost of revenues was $39.7 million, an increase from $37.2 million in the same quarter last year [7][8] Adjusted Metrics - Adjusted EBITDA for Q3 2025 was $35.2 million, a 7% increase from $33.1 million in Q3 2024 [11][8] - Adjusted net income for Q3 2025 was $22.2 million, compared to $20.3 million in Q3 2024 [13][8] - Adjusted diluted earnings per share for Q3 2025 was $0.14, slightly up from $0.13 in Q3 2024 [13][8] Guidance and Outlook - The company expects full-year adjusted EBITDA margin to be approximately 32% and adjusted diluted earnings per share in the range of $0.45 to $0.47 [15] - Certara aims to continue investing in R&D and commercial efforts to ensure sustainable long-term growth [3]